Theriva Biologics says Nature Medicine publishes VIRAGE Phase 2b results for VCN-01 in metastatic pancreatic cancer

By Public Technologies
  • Theriva Biologics highlighted peer-reviewed Nature Medicine publication of results from the VIRAGE Phase 2b trial of VCN-01 in metastatic pancreatic cancer.
  • Results were already presented via the publication, showing improved survival-related outcomes when VCN-01 was added to standard chemotherapy versus chemotherapy alone.
  • Analyses supported an immune-mediated effect alongside tumor-stroma disruption, expanding potential combination-use positioning across pancreatic cancer regimens.
  • VIRAGE2 Phase 2a is under way to test more frequent repeat dosing to support a future Phase 3 regimen decision.
  • Initial pharmacodynamic and safety-tolerability data are expected in Q3 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Theriva Biologics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609300800PRIMZONEFULLFEED9836234) on September 30, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.